Guerbet SA (LON:0ELV)

Market Cap	97.00M -58.3%
Revenue (ttm)	696.74M -6.2%
Net Income	-94.51M
EPS	-7.49
Shares Out	n/a
PE Ratio	n/a
Forward PE	5.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	919
Open	8.90
Previous Close	8.84
Day's Range	8.87 - 8.95
52-Week Range	8.10 - 23.60
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 2,746
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ELV

Financial Performance

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error